Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by biotech1973on Dec 02, 2019 4:39pm

97 Views

Post# 30414752

RE:RE:RE:RE:RE:RE:RE:TBP has found a partner

Do you know that we had 800 Million on October 1st and our burn rate is 300k a month. Considering that we should have nothing right now. Now if we have no offer or nothing in pipeline, dont you think ROB would have announced another PP in the financials. Why he wants to wait till 15th December. I know for sure that deal is on the table and their are final negotiations going on. He wants to get the best money out. HE has done in the past as well. If nothing materialises before 15th December, we will definately go for pp but for now Talks are in final stages. Read between the lines and you will get your answer

Bullboard Posts

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles